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recorded symptom scores, use of rescue medication, and time off
school and parental time off work due to asthma. RESULTS: A
total of 35 patients participated. Mean age: 9.8yrs, mean time
since diagnosis: 6.2yrs. At w16 compared with w0: Mean PEFR
increased by 59.2 l/min*; all PAQLQ domain and overall scores
improved >=2 points*; mean day and night time symptoms
scores improved by 1.5 points* and 1.6* points respectively;
patients reported a mean of 3.9 more days per week without
asthma symptoms* and 4.6 fewer days per week using short
acting b2 agonist medication*; children missed 1.6 fewer school
days per month, and carers missed a mean of 1.2 fewer days per
month from work*. No treatment related adverse events were
reported. CONCLUSION: SFC signiﬁcantly improved asthma
symptoms, quality of life and daily activities of uncontrolled
pediatric asthma patients and their families. *P < 0.05
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OBJECTIVE: The aim of this study was to assess the degree of
asthma control in Spain in accordance with the GINA criteria.
METHODS: An epidemiological cross-sectional multicenter
study was performed. A representative sample of consecutive
patients with asthma over 18 years attending primary care and
specialist ofﬁces were enrolled. Patients were seen in winter and
spring and were asked on their asthma control in the four weeks
prior to the visit according to the GINA criteria. Control was
deﬁned based on the patient’s day and night symptoms.
RESULTS: A total of 614 patients participated in the study.
Patients presented every day or most days in the four weeks prior
to the winter and spring visit daytime symptoms (40.3% vs.
22.5%) (p < 0.01), night-time symptoms (27.8% vs. 13.9%) 
(p < 0.01)), severe exacerbation episodes (11.9% vs. 8.8%) and
intolerance to exercise (32.9% vs. 35.5%). The proportion of
patients with emergency visits in the four weeks prior to the 
visit was 9.1% vs. 4.2% (p < 0.01) respectively. The most fre-
quently used treatment was the combination of inhaled corti-
costeroids and long-acting b2 adrenergic agonists (49.8% vs.
49%). There were a slightly higher number of inadequately 
controlled patients in winter than spring, 74.2% vs. 71.1% 
(p < 0.01) respectively. CONCLUSION: Asthma is poorly con-
trolled in Spain, with the need for improvements in the man-
agement of the disease.
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OBJECTIVES: A literature search revealed only a few published
retrospective database analyses in which the yearly cost of
asthma was compared for patients with and without asthma
attacks. This however does not allow estimating the health care
utilization associated with a single exacerbation. In contrast, this
study aims to analyze resource use collected during a random-
ized, double-blind trial and to estimate the costs of a mild and
a severe asthma exacerbation. METHODS: The INNOVATE
trial randomized severe persistent allergic asthma patients who
were inadequately controlled despite inhaled corticosteroid (ICS)
and long-acting beta2-agonist (LABA) to continued standard
therapy (N = 210) or to add-on therapy with omalizumab (N =
209). Resource use was recorded on the CRF and with daily
patient diaries. Data from both treatment arms were pooled to
calculate average resource use for clinically signiﬁcant (worsen-
ing of asthma symptoms requiring systemic steroids) mild (PEF
or FEV1 >= 60% of personal best) or severe (PEF or FEV1 <
60% of personal best) exacerbations from a UK NHS perspec-
tive. Patients were observed for a total of 36 weeks (including 8
weeks run-in). Standard unit costs (PSSRU, NHS Reference
Costs, 2004) were applied to calculate the exacerbation-related
cost. RESULTS: A total of 419 patients experienced 195 mild
and 204 severe exacerbations during the observation period,
lasting on average 12.8 days each. Resource use was measured
in terms of GP surgery visits, ER visits, outpatient visits, hospi-
talizations and rehabilitation visits. The average cost of a clini-
cally signiﬁcant mild exacerbation is estimated to be £99, and of
a severe exacerbation is £197. CONCLUSIONS: Exacerbations
are costly and frequently occurring events in a severe persistent
allergic asthma population. Decreasing the frequency and sever-
ity of exacerbations improves patients’ health outcomes and
reduces resource use, which could be quantiﬁed with this
approach.
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Montelukast is recognised to be an effective and safe therapy for
the treatment of mild to moderate asthmatic patients with con-
comitant seasonal allergic rhinitis. OBJECTIVES: to evaluate
asthma-related direct costs in patients with mild to moderate per-
sistent asthma and seasonal allergic rhinitis (AR) in Spain, whose
asthma was inadequately controlled and required the addition of
montelukast as part of their routine care. METHODS: a multi-
center, 12 months pre-post observational study was conducted,
selecting mild to moderate asthmatic consecutive patients with
previous inhaled corticosteroid (ICS) w/wo LABAs therapy, who
initiated concomitant montekulast between January 1999 and
December 2002. Asthma-related health care resources data was
collected retrospectively, including medication, medical visits, 
ER visits and hospitalizations. For the costing calculations,
natural units were multiplied by unit costs, and conﬁdence inter-
vals (CI) calculated using bootstrapping analysis. RESULTS:
212 patients (mean age 36.0(SD 9.7), 56.6% female, 50.9% 
mild asthmatics) were recruited in 55 sites (54.5% Primary 
Care, 34.5% Allergologists and 11% Pneumologists) across the
country. After initiation of montelukast therapy, all other
asthma-related health care resource categories did show a sig-
niﬁcant reduction (p < 0.01) (mean reduction in 2004€; 95%
CIs): medication (146.1; 78.8–225.2); outpatient visits (57.5;
44.5–76.8), ER visits (61.1; 48.4–84.4) and hospitalizations
(243; 86.2–875.4), total 508.3 95% CI 348.3–969.9. Addition-
ally considering the montelukast treatment cost during 365 days,
the reduction achieved in all other asthma-related health care
resources would compensate for 92.7% of the montelukast cost.
CONCLUSIONS: montelukast therapy was associated with a
signiﬁcant reduction in all other asthma-related health care
resources use in patients with mild to moderate asthma and con-
comitant seasonal allergic rhinitis.
